Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $289.10

ICON Public Limited (NASDAQ:ICLR) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $289.18.

Several equities analysts have recently weighed in on the company. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Robert W. Baird lowered their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. TD Cowen decreased their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Truist Financial restated a “buy” rating and set a $284.00 price target (down from $295.00) on shares of ICON Public in a research report on Wednesday, December 18th. Finally, Barclays cut their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th.

ICON Public Price Performance

ICON Public stock opened at $215.51 on Thursday. The stock has a market capitalization of $17.78 billion, a P/E ratio of 24.03, a P/E/G ratio of 1.54 and a beta of 1.20. The company’s fifty day moving average price is $211.79 and its 200 day moving average price is $274.18. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.10 EPS. As a group, equities research analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

A number of hedge funds and other institutional investors have recently modified their holdings of ICLR. GAMMA Investing LLC increased its position in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. Foyston Gordon & Payne Inc acquired a new stake in ICON Public in the 3rd quarter valued at approximately $11,672,000. Icon Wealth Advisors LLC raised its position in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after purchasing an additional 11,840 shares during the period. First Horizon Advisors Inc. lifted its stake in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares in the last quarter. Finally, Arkadios Wealth Advisors boosted its position in shares of ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after buying an additional 62 shares during the period. 95.61% of the stock is owned by institutional investors and hedge funds.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.